Screener
Corcept Therapeutics CORT Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $111,039 | $120,495 |
| Short-term marketable securities | 197,158 | 251,657 |
| Trade receivables, net of allowances | 76,920 | 59,786 |
| Inventory | 13,185 | 12,868 |
| Prepaid expenses and other current assets | 41,374 | 40,658 |
| Total current assets | 439,676 | 485,464 |
| Strategic inventory | 18,956 | 11,094 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's accounts receivable?
- Corcept Therapeutics (CORT) reported accounts receivable of $76.92M in Q2 2026.
- How has Corcept Therapeutics's accounts receivable changed year-over-year?
- Corcept Therapeutics's accounts receivable increased by 19.1% year-over-year, from $64.57M to $76.92M.
- What is the long-term trend for Corcept Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), Corcept Therapeutics's accounts receivable has grown at a 17.9% compound annual growth rate (CAGR), from $26.2M to $59.79M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Corcept Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude